Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers
- PMID: 17870468
- PMCID: PMC2766800
- DOI: 10.1016/j.sbi.2007.08.017
Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers
Abstract
Proteins of the low-density lipoprotein receptor family transport cholesterol-carrying particles into cells, clear protease-inhibitor complexes from the circulation, participate in biological signaling cascades, and even serve as viral receptors. These receptors utilize clusters of cysteine-rich LDL receptor type-A (LA) modules to bind many of their ligands. Recent structures show that these modules typically exhibit a characteristic binding mode to recognize their partners, relying primarily on electrostatic complementarity and avidity effects. The dominant contribution of electrostatic interactions with small interface areas in these complexes allows binding to be regulated by changes in pH via at least two distinct mechanisms. The structure of the subtilisin/kexin family protease PCSK9, a newly identified molecular partner of the LDLR also implicated in LDL-cholesterol homeostasis, also raises the possibility that the LDLR and its related family members may employ other strategies for pH-sensitive binding that have yet to be uncovered.
Figures





Similar articles
-
Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH.EMBO Rep. 2011 Dec 1;12(12):1300-5. doi: 10.1038/embor.2011.205. EMBO Rep. 2011. PMID: 22081141 Free PMC article.
-
Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor.J Biol Chem. 2014 Jan 10;289(2):942-55. doi: 10.1074/jbc.M113.514067. Epub 2013 Nov 13. J Biol Chem. 2014. PMID: 24225950 Free PMC article.
-
Molecular basis for LDL receptor recognition by PCSK9.Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1820-5. doi: 10.1073/pnas.0712064105. Epub 2008 Feb 4. Proc Natl Acad Sci U S A. 2008. PMID: 18250299 Free PMC article.
-
On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.Atherosclerosis. 2015 Feb;238(2):264-70. doi: 10.1016/j.atherosclerosis.2014.12.017. Epub 2014 Dec 17. Atherosclerosis. 2015. PMID: 25544176 Free PMC article. Review.
-
Sorting an LDL receptor with bound PCSK9 to intracellular degradation.Atherosclerosis. 2014 Nov;237(1):76-81. doi: 10.1016/j.atherosclerosis.2014.08.038. Epub 2014 Sep 2. Atherosclerosis. 2014. PMID: 25222343 Review.
Cited by
-
LDLR, LRP1, and Megalin redundantly participate in the uptake of Clostridium novyi alpha-toxin.Commun Biol. 2022 Sep 5;5(1):906. doi: 10.1038/s42003-022-03873-0. Commun Biol. 2022. PMID: 36064583 Free PMC article.
-
An original infection model identifies host lipoprotein import as a route for blood-brain barrier crossing.Nat Commun. 2020 Nov 30;11(1):6106. doi: 10.1038/s41467-020-19826-2. Nat Commun. 2020. PMID: 33257684 Free PMC article.
-
Synthesis of multi-module low density lipoprotein receptor class A domains with acid labile cyanopyridiniumylides (CyPY) as aspartic acid masking groups.RSC Chem Biol. 2023 Jan 24;4(4):292-299. doi: 10.1039/d2cb00234e. eCollection 2023 Apr 5. RSC Chem Biol. 2023. PMID: 37034404 Free PMC article.
-
Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β.Brain. 2012 Jul;135(Pt 7):2155-68. doi: 10.1093/brain/aws127. Epub 2012 May 26. Brain. 2012. PMID: 22637583 Free PMC article.
-
Inhibition of thrombotic properties of persistent autoimmune anti-β2GPI antibodies in the mouse model of antiphospholipid syndrome.Blood. 2014 Feb 13;123(7):1090-7. doi: 10.1182/blood-2013-08-520882. Epub 2013 Nov 25. Blood. 2014. PMID: 24277078 Free PMC article.
References
-
- Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34–47. - PubMed
-
- Goldstein JL, Hobbs HH, Brown MS. Familial Hypercholesterolemia. In: Scriver CS, Beaudet AL, Sly WS, Vallee DV, editors. The Metabolic and Molecular Bases of Inherited Disease. 8. McGraw Hill Inc; 2001. pp. 2863–2913.
-
- Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154–156. *This paper reports the identification of gain of function mutations in PCSK9 as a third cause of autosomal domainant hypercholesterolemia. - PubMed
-
- Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37:161–165. **This manuscript reports the important finding that loss-of-function mutations in PCSK9 are associated with hypocholesterolemia. Importantly, such individuals are apparently healthy, suggesting that pharmacologic inhibition of PCKS9 may be a viable new therapeutic approach for reducing LDL-cholesterol in humans. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous